Antiplatelet therapy - a pharmacologist's perspective
Author:
- Jan BultasJBJan Bultas
- 1 April 2013
- journal article
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 55 (2) , e86-e94
Abstract
There are only few areas of cardiology that have witnessed such dramatic innovations as that occurring in the treatment and prophylaxis of thrombotic events. Antithrombotic (i.e., antiplatelet and anticoagulation) therapy plays a pivotal role in the prophylaxis of the pandemic of cardiovascular disease. Given the host of triggers activating primary hemostasis, various therapeutic strategies are currently available. The current approach, monotherapy or dual therapy or, possibly, combination therapy with antiplatelet and anticoagulant agents is selected based on the risk of a thrombotic event, dominant disease, and the risk of bleeding.The main problem associated with the current therapeutic strategy was not an insufficient effect, but major inter-individual variability of effect resulting in therapy failure or an unacceptable risk of bleeding documented in a non-negligible proportion of patients. Hence there is a drive for devising new antiplatelet strategies and innovation in (already) established classes of drugs.Milestones in the evolution of antiplatelet therapy included the advent of new, more effective and/or safer antiplatelet agents inhibiting platelet activation. The new irreversible P2Y12 receptor antagonist prasurgel and reversible P2Y12 receptor antagonist ticagrelor have been approved for clinical use. There has also been major progress in the development of thrombin protease-activated receptor 1 (PAR-1) antagonists (vorapaxar, atopaxar) or serotonin receptor blockers (sarpogrelat). Another promising therapeutic strategy is targeted at platelet stabilization through increased cyclic adenosine monophosphate (cAMP) activity by platelet phosphodiesterase-3 inhibition (cilostazol). Further, new insights into the bioavailability of acetylsalicylic acid under specific conditions have been reported regarding the class of agents inhibiting thromboxane A2-mediated activationKeywords
This publication has 15 references indexed in Scilit:
- Protease-activated receptor 1 (PAR1) signalling desensitization is counteracted via PAR4 signalling in human plateletsBiochemical Journal, 2011
- Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched studyBMJ, 2011
- Platelet glycoprotein IIIa (platelet antigen 1/platelet antigen 2) polymorphism and 1-year outcome in patients with stable coronary artery diseaseBlood Coagulation & Fibrinolysis, 2010
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trialThe Lancet, 2010
- Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysisThe Lancet, 2010
- The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery diseaseThrombosis and Haemostasis, 2009
- Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide‐induced tumour necrosis factor‐α generationBritish Journal of Pharmacology, 1997
- Triflusal vs aspirin on the inhibition of human platelet and vascular cyclooxygenaseGeneral Pharmacology: The Vascular System, 1992
- Preparation and Analysis of Deuterium-Labeled Aspirin: Application to Pharmacokinetic StudiesJournal of Pharmaceutical Sciences, 1985
- Dose-Related Kinetics of AspirinNew England Journal of Medicine, 1984